SALT LAKE CITY, March 5, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that its platform technology will be featured at the U.S. House of Representatives' Health Care Innovation Showcase in Washington, DC on March 7, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
The Health Care Innovation Showcase is organized by the Health Care Innovation Caucus led by U.S. Representatives Mike Kelly (R-PA), Ron Kind (D-WI), Markwayne Mullin (R-OK) and Ami Bera, M.D. (D-CA). This bipartisan caucus was founded last year with the stated goal of advancing a legislative agenda that encourages innovative policy ideas to improve the quality of care and lower costs for consumers. The Showcase will be attended by members of Congress and their staff.
PolarityTE will share its platform technology and first product, SkinTE™. The SkinTE™ product is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement, currently commercially available in a limited market release in the U.S.
"We continue to seek opportunities to share our innovative platform technology and product with various stakeholders, and we are thrilled to share our work with members of Congress at the Health Care Innovation Showcase among a diverse, prestigious group of established and emerging leaders in health care," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE. "This unique forum allows the company to highlight the potential impact true tissue regeneration can have on health care. We applaud and share the goals of the Caucus to advance and support innovation to ultimately deliver better results to patients at lower overall costs. We look forward to joining these conversations and broadening the dialog around improving health care."
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
VP, Investor Relations
LifeSci Advisors, LLC
SOURCE PolarityTE, Inc.